Brain and nervous system diseases

Alzheimer's disease
Kirby J, Green C, Loveman E, Clegg A, Picot J, Takeda A et al. A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease. Drugs and Aging 2006;23(3):227-240.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. Clinical and cost effectiveness of Donepezil, Rivastigmine, Galantamine and Memantine for Alzheimer's dementia. Health Technology Assessment 2006;10(1).

Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modeling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately-severe Alzheimer's disease. Pharmacoeconomics 2005;23(12):1271-82.

Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. International Journal of Geriatric Psychiatry 2005;21:17-28.

Multiple Sclerosis

Loveman E, Cummins E, Melendez-Torres GJ et al. Daclizumab for treating relapsing–remitting multiple sclerosis. A Single Technology Appraisal. 2017


Back to main publications page

  • Scoping
  • Protocol
  • Literature searching
  • Eligibility screening
  • Data extraction and critical appraisal
  • Data synthesis
  • Conclusions and recommendations